Barclays Increases Price Target for Johnson & Johnson Amid Strong Pharmaceutical Performance
Barclays has raised its price target for Johnson & Johnson (NYSE: JNJ) from $234 to $255, reflecting confidence in the company's pharmaceutical division. Analyst Matt Miksic highlighted that the pharmaceutical unit has shown significant momentum, marking its sixth consecutive quarter of strong performance.
Despite the increase in the price target, Barclays maintained an Equal Weight rating on Johnson & Johnson shares. The company is also recognized as one of the top ten healthcare stocks with the highest dividends, further emphasizing its stability and attractiveness to investors.
© 2026 KLEA News. All Rights Reserved. This article is provided for informational purposes only. It is not offered or intended to be used as legal, tax, investment, financial, or other advice.
Source: KLEA News